Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: DIPG Clear all
Recruiting Phase 1 Interventional

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

NCT07076498
View directory record Official record
Conditions
Glioma
Interventions
M032
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

NCT05630209
View directory record Official record
Conditions
Brain Tumor
Interventions
Exablate, Doxorubicin
Device · Drug
Lead sponsor
InSightec
Industry
Eligibility
5 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Miami, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers

NCT03538587
View directory record Official record
Conditions
Glioblastomas, Sarcoma, Astrocytoma, Brain Cancer, Leukemia
Interventions
Enhanced Mindfulness Intervention, Psychoeducation
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 24 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 21, 2026, 4:42 PM EDT
Suspended Phase 1Phase 2 Interventional

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

NCT06639607
View directory record Official record
Conditions
Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma, Ependymoma
Interventions
PEP-CMV vaccine, Tetanus booster, Nivolumab, Temozolomide
Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
4 Years to 25 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2051
U.S. locations
3
States / cities
St Louis, Missouri • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Terminated Phase 1Phase 2 Interventional

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Early Phase 1 Interventional

Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma

NCT02992015
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
Gemcitabine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Results available

Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

NCT02717455
View directory record Official record
Conditions
Glioma
Interventions
LBH589
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
2 Years to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Jul 21, 2026, 4:42 PM EDT
Recruiting Phase 2 Interventional

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

NCT05096481
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Interventions
PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
Biological · Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

NCT03605550
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
PTC596, Radiotherapy
Drug · Radiation
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Months to 21 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Recruiting Phase 2 Interventional

Study of Olutasidenib and Temozolomide in HGG

NCT06161974
View directory record Official record
Conditions
High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
Interventions
Olutasidenib + TMZ
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
12 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Active, not recruiting Phase 1 Interventional

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

NCT03478462
View directory record Official record
Conditions
Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
Interventions
CLR 131
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
Palo Alto, California • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

NCT01837862
View directory record Official record
Conditions
Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma, Pleomorphic Xanthoastrocytoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma, Diffuse Intrinsic Pontine Glioma, DIPG, Low-grade Glioma, Brainstem Glioma
Interventions
Mebendazole, Vincristine, Carboplatin, Temozolomide, Bevacizumab, Irinotecan
Drug
Lead sponsor
Julie Krystal
Other
Eligibility
1 Year to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 21, 2026, 4:42 PM EDT
Active, not recruiting Phase 1 Interventional

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

NCT02359565
View directory record Official record
Conditions
Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma, Refractory Brain Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Ependymoma, Refractory Medulloblastoma
Interventions
Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-enhanced MR Perfusion, Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging, Magnetic Resonance Spectroscopic Imaging, Pembrolizumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Recruiting No phase listed Observational

xPedite: A Study to Expedite DIPG and DMG Research

NCT06140719
View directory record Official record
Conditions
Oncology, DIPG, DMG
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 21, 2026, 4:42 PM EDT
Recruiting Phase 2 Interventional

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

NCT06838676
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Gliomas (DIPG), Progressive DIPG, Refractory DIPG, Recurrent DIPG, H3K27-altered High Grade Glioma
Interventions
ACT001
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Months to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
12
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 1 Interventional

Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas

NCT01222754
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, High Grade Glioma
Interventions
Lenalidomide, XRT, 54-59.4 Gy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Jul 21, 2026, 4:42 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

NCT03330197
View directory record Official record
Conditions
Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
Interventions
Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
0 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 1 Interventional

Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).

NCT01688401
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma (DIPG)
Interventions
Melphalan hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Month to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Jul 21, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

NCT03257631
View directory record Official record
Conditions
Central Nervous System Neoplasms, Medulloblastoma
Interventions
Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
1 Year to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Jul 21, 2026, 4:42 PM EDT
Recruiting Phase 1 Interventional

PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

NCT04837547
View directory record Official record
Conditions
Neuroblastoma, Diffuse Intrinsic Pontine Glioma
Interventions
Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
Biological
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
3
States / cities
Gainesville, Florida • Charlotte, North Carolina • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Recruiting Phase 2 Interventional

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Trial

NCT05077735
View directory record Official record
Conditions
Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
Hypofractionated Radiation Therapy, Questionnaire Administration, Magnetic Resonance Imaging, Computed Tomography Scan
Radiation · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Recruiting Phase 1 Interventional

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

NCT04196413
View directory record Official record
Conditions
Glioma of Spinal Cord, Glioma of Brainstem
Interventions
GD2 CAR T cells, Fludarabine, Cyclophosphamide, Rituximab
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2043
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 21, 2026, 4:42 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

NCT04730349
View directory record Official record
Conditions
Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma
Interventions
Nivolumab, NKTR-214
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Little Rock, Arkansas • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 21, 2026, 4:42 PM EDT
Terminated Phase 1 Interventional

Phase I Study of Marizomib + Panobinostat for Children With DIPG

NCT04341311
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer, Pediatric Brain Tumor, Diffuse Glioma
Interventions
Marizomib, Panobinostat
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Jul 21, 2026, 4:42 PM EDT